Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Publikation

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Wissenschaftlicher Artikel/Review - 08.10.2016

Ferris Robert L, Blumenschein George, Fayette Jerome, Guigay Joel, Colevas A Dimitrios, Licitra Lisa, Harrington Kevin J, Kasper Stefan, Vokes Everett, Even Caroline, Worden Francis, Saba Nabil F, Iglesias Docampo Lara Carmen, Haddad Robert, Rordorf Tamara, Kiyota Naomi, Tahara Makoto, Monga Manish, Lynch Mark, Geese William J, Kopit Justin, Shaw James W, Gillison Maura L

Zitation

Ferris R, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Saba N, Iglesias Docampo L, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese W, Kopit J, Shaw J, Gillison M. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016; 375:1856-1867.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

N Engl J Med 2016; 375

Veröffentlichungsdatum

08.10.2016

eISSN (Online)

1533-4406

Seiten

1856-1867

Kurzbeschreibung/Zielsetzung

Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition.